These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 33852477)
21. Vericiguat, sacubitril/valsartan and more evidence that we are failing our patients. Butt JH; McMurray JJV Eur J Heart Fail; 2022 Sep; 24(9):1623-1624. PubMed ID: 35919944 [No Abstract] [Full Text] [Related]
22. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure. Rodgers JE Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069 [TBL] [Abstract][Full Text] [Related]
23. A narrative review on sacubitril/valsartan and ventricular arrhythmias. Wei Z; Zhang M; Zhang Q; Gong L; Wang X; Wang Z; Gao M; Zhang Z Medicine (Baltimore); 2022 Jul; 101(27):e29456. PubMed ID: 35801732 [TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective. Chin KL; Zomer E; Wang BH; Liew D Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468 [TBL] [Abstract][Full Text] [Related]
25. Heart Failure Phenotypes According to Natriuretic Peptide Trajectory Following Initiation of Sacubitril/Valsartan. Mohebi R; Liu Y; Myhre PL; Felker GM; Prescott MF; Piña IL; Butler J; Ward JH; Solomon SD; Januzzi JL JACC Heart Fail; 2023 Jul; 11(7):855-858. PubMed ID: 37115131 [No Abstract] [Full Text] [Related]
26. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure]. Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045 [TBL] [Abstract][Full Text] [Related]
27. Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure. Sangaralingham LR; Sangaralingham SJ; Shah ND; Yao X; Dunlay SM Circ Heart Fail; 2018 Feb; 11(2):e004302. PubMed ID: 29453287 [TBL] [Abstract][Full Text] [Related]
29. Loop diuretic management after sacubitril/valsartan initiation in heart failure with preserved ejection fraction: deceptively simple or more than meets the eye? Sinha A; Patel RB Eur J Heart Fail; 2023 Jan; 25(1):95-97. PubMed ID: 36445011 [No Abstract] [Full Text] [Related]
30. The interplay between sacubitril/valsartan, heart failure with preserved ejection fraction, diabetes and kidney function. Voordes GHD; Heerspink HJL; Ter Maaten JM Eur J Heart Fail; 2022 May; 24(5):804-806. PubMed ID: 35415946 [No Abstract] [Full Text] [Related]
31. Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States. Bhatt AS; Vaduganathan M; Lee SB; Desai RJ JACC Heart Fail; 2023 Aug; 11(8 Pt 1):1021-1023. PubMed ID: 37227387 [No Abstract] [Full Text] [Related]
32. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. King JB; Shah RU; Bress AP; Nelson RE; Bellows BK JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128 [TBL] [Abstract][Full Text] [Related]
33. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure. Marques da Silva P; Aguiar C Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335 [TBL] [Abstract][Full Text] [Related]
34. Optimal Therapeutic Strategy Using Sacubitril/Valsartan in a Patient with Systolic Heart Failure and Chronic Kidney Disease - An Initial Case Report in Japan. Imamura T; Hori M; Kinugawa K Intern Med; 2021; 60(17):2807-2809. PubMed ID: 34470986 [TBL] [Abstract][Full Text] [Related]
35. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Nougué H; Pezel T; Picard F; Sadoune M; Arrigo M; Beauvais F; Launay JM; Cohen-Solal A; Vodovar N; Logeart D Eur J Heart Fail; 2019 May; 21(5):598-605. PubMed ID: 30520545 [TBL] [Abstract][Full Text] [Related]
36. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction. Nguyen E; Weeda ER; White CM J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162 [TBL] [Abstract][Full Text] [Related]
37. Sacubitril-valsartan modifies the indication of cardiac implantable devices in patients with heart failure and reduced ejection fraction. Belarte-Tornero LC; Mojón D; Solé-González E; Ruiz-Bustillo S; Valdivielso-More S; Farré N Rev Esp Cardiol (Engl Ed); 2021 Dec; 74(12):1117-1119. PubMed ID: 34247968 [No Abstract] [Full Text] [Related]
38. Letter to the Editor regarding to 'Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control'. Wewer Albrechtsen NJ; Bojsen-Møller KN Int J Cardiol; 2022 Dec; 368():55. PubMed ID: 36037929 [No Abstract] [Full Text] [Related]
39. Angiotensin-Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: You Win Some, You Lose Some. Ventura HO; Lavie CJ; Mehra MR J Am Coll Cardiol; 2023 Jul; 82(1):13-15. PubMed ID: 37220861 [No Abstract] [Full Text] [Related]